Syrma SGS Technology Ltd
NSE:SYRMA · BSE:543573 · Electronics manufacturing services · Primaegis Equity Desk · 06 Aug 2026
The operating story is sound. The price has already spent it. Revenue scaled from ₹1,267 Cr (FY22) to ₹4,819 Cr (FY26), with no pledge, no encumbrance and no non-disposal undertaking at any of five quarter-ends tested. But the shares trade at 87.02× FY26 earnings against the company's own equal-weighted filed-year median of 48.54× — and on the base case, with guidance delivered in full, that returns +0.83% in total to FY29.
Close of record ₹1,434.10 — settled NSE close, 05-Aug-2026. Seven agents · two adversarial gates · gate 2 rejected three sections for damage the repairs introduced.
How to read this report
This desk publishes its audit trail. Chips after a claim tell you where the number came from and how far to trust it:
| filing + date | Primary filing — read off an exchange filing, annual report or investor deck. Strongest tier. |
| raw.json | Traceable to the desk's gathered data — re-checkable at that location. |
| devil gate | Found by the adversarial reviewer, not the analysts — challenged, corrected or withdrawn under attack. |
| GAP | Not disclosed, or not captured. An absence recorded rather than filled. |
| SECONDARY | Unverified media or aggregator sourcing. Carried for context, never load-bearing. |
| DERIVED | Computed by the desk from filed inputs, with the arithmetic shown. |
Colour is signal, never decoration. Green and red mark favourable and unfavourable data only. Variance cells carry ▲/▼ with the delta so direction survives in greyscale.
⚠️ Price of record — and the tell that settled it
Adopted: ₹1,434.10, the settled NSE close of 05-Aug-2026. The corpus carried ₹1,427.00 from a capture stamped 14:32 IST — an hour before the close.
The decisive tell was not the timestamp but the tape: cumulative volume ROSE across three successive pulls of the same date. A settled close cannot print rising cumulative volume. A sixth pull later the same day came back at 1,418.00 on 1,236,471 shares — up again from 1,173,883.
The restatement made every conclusion worse, not better — the base case halves from +0.50% to +0.31% p.a. All five sections are now on ₹1,434.10; ₹1,427.00 survives only where labelled provisional.
Part A — Fundamentals
A1–A5. The scaling is real and filed
Syrma SGS is an electronics manufacturing services group whose revenue went ₹1,267 Cr (FY22) → ₹2,048 → ₹3,154 → ₹3,787 → ₹4,819 Cr (FY26). Q4 FY26 operating EBITDA was ₹1,741.49 Mn at an 11.89% margin, re-derived from the filing rather than taken from the deck — a correction the desk made to its own earlier figure.
devil gate One number in circulation is not what it appears: a ₹318 Cr owners'-PAT figure is a broker model, not a filed number, and is labelled as such everywhere it appears.
🚨 Order-book coverage is falling — and the desk had to force its own sections to agree
| Order book ÷ TTM revenue | to 30-Jun-2025 | to 30-Jun-2026 | Change |
|---|---|---|---|
| Coverage | 1.51× | 1.24× | ▼ −0.27 turns, −18.1% |
The sharper cut is forward: the twelve-month executable book covers only 83.0% of guided FY27 revenue, leaving ₹1,106 Cr that must be both won and executed inside the same year. Severity escalates to 🔴 below 1.10×.
This metric had two opposite verdicts in the corpus until the second gate. The forensic section had withdrawn the comparison as unrunnable, saying a quarter was missing from the dataset — all four quarters it needed were on disk, and the fundamental section had already run exactly that computation. The desk now carries one figure, with the eight quarterly inputs and the arithmetic inline.
A10 / A16. Valuation — the whole position
| At ₹1,434.10 | Multiple | Against its own history |
|---|---|---|
| P/E on FY26 EPS | 87.02× | +79.3% above its own equal-weighted median of 48.54× |
| P/E on TTM EPS | 75.08× | +8.2% above the recency-weighted p80 of 69.42× |
| vs own recency p80 | +25.4% | …and the p80 is an interpolation pulled upward by FY24's 80.85× |
| vs the highest multiple it has EVER printed | +7.6% | Above its own maximum filed-year P/E. |
What that costs, on full delivery of guidance:
| FY29 outcome | Total | Annualised |
|---|---|---|
| Base case | +0.83% | +0.31% p.a. |
| Probability-weighted | +9.9% | +3.6% p.a. — below cash |
| Bear | −29.7% | — |
| Bull | +73.8% | — |
The base case delivers under one percent in total over roughly two and a half years, with management's guidance delivered in full. The required terminal value to clear the desk's hurdle is ₹1,985.03; sustaining today's multiple needs a +35.4% earnings CAGR on the company's own median exit. The distribution is wide — but its centre does not pay.
The single external check points the same way
Exactly one broker note exists — ICICI Securities Retail Research, 31-Jul-2026, BUY, target ₹1,680. That target is struck at 52× FY28E EPS.
Fifty-two times is 40.2% BELOW today's 87.02× — and only 7.1% above the desk's own median exit of 48.55×. The one bull in the market is not defending this multiple either; its target embeds a large de-rating. The disagreement is entirely EPS: at an identical 52×, the desk's base case gives ₹1,271 and ICICI gives ₹1,680, because its FY28E EPS sits +32.1% above a fully-delivered base case and +16.6% above even the bull path.
Part B — Technical: Stage 2 intact, but the location is wrong
Stage 2 confirmed 17-Apr-2026 and not since challenged. The 30-week MA turned up that week (795.79, +5.02) with price 22.91% above it, and it is still rising at ~+21 a week and accelerating. Stage 3 evidence: none on the primary test — price has never closed below the line.
Where it is stretched is the whole technical case: price sits +38.94% above the 30-week line and +50.33% above the true 200-day SMA. Both Weinstein and Minervini want Stage 2 entries near the line, not fifty percent above it.
B4. The section revised its own answer — and the revision is instructive
Revision 1 answered a flat no, dismissing ₹1,421.60 as a “two-day shelf”. On a full re-pull it is a four-touch shelf across five weeks, so the 2.75% stop it anchors is structural rather than incidental.
The answer is now a qualified yes: one compliant construction exists — entry ~₹1,455 on a settled close above ₹1,451.90, close-basis stop ₹1,415, 1.57:1 to ₹1,517.70 — but it sits inside the densest volume band on the chart, and a well-located stop costs 6.19% instead.
Both numbers are published and the change is flagged in-section rather than silently restated. No entry today: the trigger has not fired.
A methodological note worth carrying. Rebuilding the weekly series turned up a 0.02% residual against TradingView that Revision 1 had excluded as an anomaly. It was one real bar — TradingView closes the week of 26-Jan on the Sunday 01-Feb-2026 special session (3.43 m shares, 23% delivery). Adopting it ties the hand computation to ten significant figures. No conclusion moved; the excluded “anomaly” was the desk's own error.
A13 / A12b. Capital, governance and the widening perimeter
Genuinely clean, and it should not be lost
- No pledge, no encumbrance, no non-disposal undertaking at ANY of five quarter-ends now tested — upgraded from a single-point check to a trend.
- The promoter reduction traces entirely to one holder — Modern Die Casting LLP, −1,177,552 shares in two tranches. The two largest holders are unchanged at all five dates.
- Forensic filter: 1 🔴 · 7 ⚠️ · 4 ✓ · 1 split — no fraud finding.
- Dissent is concentrated on directors (14.28% against one) and not on capital (0.15% on the QIP).
What is open
- A ₹1,000 Cr QIP enabler, voted 25-Aug-2026 — nineteen days after this report's data date. 7,339,988 shares = 3.81% dilution. Less than half the Aug-2025 QIP's 8.03%, because market cap has more than doubled — but that precedent took a 4.98% discount, near the permitted maximum. Sought at three consecutive AGMs, converted once in two.
- The related-party perimeter widened: foreign promoter-group entities 9 → 10. On Medistreams, Infinx Inc. was already a promoter-group body corporate in the same filing — so the categorisation is filing-established. The mechanism is not, and the desk explicitly refuses to assert it. Consideration, rationale, acquirer and Reg 23 status are all undisclosed.
- A five-seat independence cliff: all five independent directors sit on a synchronised second-term clock from 17-Sep-2024, leaving one seat of headroom.
- The statutory auditor was appointed — not re-appointed — 17-Sep-2024, so roughly two years in, on 2.64% dissent.
C4. Alignment — DIVERGING
The lenses genuinely disagree, and the valuation dominates because it is the least assumption-dependent. The technical read needs a judgement about whether +38.94% extension matters; the order-book read needs a view on FY27 wins. The valuation needs neither: the shares trade above the highest multiple this company has ever printed, and on full delivery of management's own guidance the base case returns under one percent in total over two and a half years.
C7. PRIMAEGIS opinion — REDUCE
The rating logic gives REDUCE for deteriorating fundamentals or stretched valuation. The fundamentals are not deteriorating — the valuation is stretched, and it is stretched on the company's own history rather than against a peer set. 87.02× sits above the highest filed-year multiple Syrma has ever printed, and the recency-weighted p80 that appears to accommodate it is an interpolation pulled up by a single year.
The number that decides it is not the multiple but its consequence: on the base case, with guidance delivered in full, the shares return +0.83% in total to FY29 — +0.31% a year. The probability-weighted outcome is +9.9% total, +3.6% a year, which is below cash.
Three things are genuinely good and should not be lost: a clean capital-structure record across five quarters of registers; a forensic filter returning one flag against four clean and seven cautions with no fraud finding; and operating scaling since FY22 that is real, filed and large.
⬆ Upgrade to NEUTRAL if any TWO of:
- Order-book coverage back above 1.5× on disclosed wins.
- A de-rating to within ~15% of the own-median 48.54× without an earnings downgrade — the multiple, not the business, does the adjusting.
- Medistreams acquires a disclosed consideration, rationale and Reg 23 treatment, and the promoter-group roster stops widening.
⬇ Downgrade to SELL if any ONE of:
- Coverage below 1.10× — the desk's own stated escalation trigger.
- The QIP is drawn at a discount near the permitted 5% maximum, repeating the Aug-2025 pattern at a materially higher multiple.
- A settled weekly close below the 30-week MA — ending Stage 2 and removing the only lens currently pointing up.
- Any independent-director resignation — one seat of headroom against a five-seat synchronised cliff.
⚠️ SEBI: Internal analyst opinion only. Primaegis is not a SEBI-registered investment adviser or research analyst. This is research framing, not a buy or sell recommendation, and nothing here is personalised investment advice.
Provenance — two gates, and what the second one caught
Gate 1 rejected two sections. Gate 2 confirmed every substantive gate-1 fix had landed — and then rejected three sections for a different failure: sections asserting a state of the corpus that their colleagues' revisions had since falsified. That is the second time on this batch that the damage found at re-gate was introduced by the repair rather than surviving it. It is the reason the second gate exists.
Three instances, all now closed: two sections still described four shareholding filings as “not on disk” after all four had been re-fetched; one left a [VERIFIED] tag pointing at moving-average inputs the artifact did not preserve (fixed by preserving the full 272-session daily and 57-week weekly series, not by downgrading the tag); and one withdrew an order-book comparison as unrunnable on the stated ground that a quarter was missing — when all four quarters were on disk and another section had already run it.
One arbitration the orchestrator made and an analyst then improved on. Four sections carried three QIP share counts. The desk adopted 7,339,988 at ₹1,362.40 reasoning that a two-decimal price is the precision Indian issuers file at. The forensic section then supplied a proof rather than a plausibility argument: SEBI caps the discount at 5%, and ₹1,362.40 is the only two-decimal price that does not breach it — ₹1,362.39 prices at 5.00035%. It also established that retrieving a filed count was impossible in principle, the resolution not being voted until nineteen days after the data date. The spread across the three candidates is 566 shares on 7.34 million — 0.0077%, and all three round to 3.81%.
A scratchpad collision was found and independently verified as repaired. Two files in the shared scratchpad held another company's shareholding data under Syrma's expected filenames. All four registers were re-fetched from Syrma's own disclosure index. The gate did not take that on the analyst's word: it reproduced four independent ties, the strongest being FPI Category I+II 12,736,840 → 14,492,258 = +1,755,418, exactly the largest inflow item in the already-balanced quarterly register reconciliation. No Syrma section carries a figure derived from the wrong company.
